Background Patients with attention-deficit/hyperactivity disorder (ADHD) are more prone to physical injuries, including motor vehicle accidents, fractures and brain injuries. Several observational studies have been published investigating the association between the use of pharmacological treatment for ADHD and the incidence of physical injuries among patients with ADHD; however, the findings are not concordant. Objective This study is a systematic review and metaanalysis of the existing literature and estimates the overall association between the use of ADHD medications and physical injury. Injury is defined as medically attended physical injuries in the form of hospitalisations, emergency department visits or general practitioners visits. Methods The PubMed, EMBASE, PsycINFO, CINAHL and Cochrane Review databases were searched for relevant studies published up to May 2017 relating to ADHD medication and risk of injuries. Observational studies with any study design, all age groups (children and adults) and all ADHD medications (stimulant and non-stimulants) were included. Studies relevant to the association between ADHD medication exposure and risk of injuries in ADHD patients were extracted and compiled for meta-analysis. Both within-individual and between-individual analyses were conducted. Results Overall, 2001 citations were identified and 10 observational studies were included. Three self-controlled case series and two self-controlled cohorts were eligible for meta-analysis of within-individual studies. Five cohort studies were included in the meta-analysis of between-individual studies. The adjusted rate ratio of the within-individual methods was 0.76 (95% confidence interval [CI] 0.61-0.93) and 0.88 (95% CI 0.85-0.92) for between-individual studies. Conclusion The findings of this meta-analysis support a reduced risk of injuries among ADHD patients who were treated with ADHD medications.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by hyperactivity, impulsivity, and cognitive dysfunction [1, 2] . ADHD often causes a major negative impact in one's daily life and generally patients with ADHD are more prone to injuries, including motor vehicle accidents, fractures and brain injuries [3] . Risk of injury to children and adolescents with ADHD might be mediated by several factors, such as impairment of motor functions, developmental coordination disorders or other core symptoms [4] . Indeed, core ADHD symptoms, such as impulsivity, inhibitory deficits and inattention to surroundings, may be major factors in accidents. Pharmacological treatments such as methylphenidate, dexamphetamine, or atomoxetine are effective in the treatment for ADHD symptoms [1] . Stimulant medication use was hypothesised to decrease injury risk by reducing ADHD symptoms such as inattention or impulsivity [5, 6] . Indeed, a large number of the studies based on artificial laboratory simulations have shown that ADHD treatment reduces 'errors and accidents' [7] . Some published studies have reported the association between ADHD medications and a lower risk of injuries in ADHD [5, 6] , while others did not report the same findings [8, 9] . The impact of ADHD medications in the prevention of physical injury still remains uncertain. In view of the above issues, we undertook a systematic review and meta-analysis of published studies to evaluate the effectiveness of ADHD medications in reducing injuries in the real-life setting.
Method
A systematic literature search was conducted using the search terms listed in Appendix. The PubMed, EMBASE, PsycINFO, CINAHL and Cochrane Review databases were searched up to 15 May 2017. Only English-language studies were included. Titles and abstracts were screened and full texts of relevant articles were retrieved for further review to identify relevant studies. This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure clear and comprehensive reporting.
Inclusion and Exclusion Criteria
Inclusion criteria were (1) analytical observational studies using cohort, case control, self-controlled case series (SCCS) or case-crossover study design; (2) studies must report the association between ADHD medication use, stimulants and/or non-stimulants, and the risk of injuries. (injuries are defined as ''medically attended physical injuries in the form of hospitalisations, emergency department [ED] visits or general practitioner [GP] visits''; and (3) studies on children, adolescents and/or adults. Exclusion criteria were (1) case reports and (2) animal studies.
Quality Assessment
As recommended by the Cochrane Collaboration [10] , the included studies were assessed for methodological quality using the Newcastle-Ottawa scale (NOS) [11] . Three authors (ML, EM and SL) independently reviewed and scored each study. Disagreements were resolved through discussions. A maximum of nine stars could be allocated for the selection, comparability and outcome categories. The total score was obtained by adding the number of stars in the subcategories, where a higher score indicated better quality.
Data Extraction
Data from the included studies were extracted using a standardised data collection form. These included study duration and design, data source, outcome definition and effect size. Four authors (ML, EM, SL and WQ) independently extracted data and completed the characteristics form that was subsequently cross-matched to ensure consistency and accuracy. Information for each study was extracted by two authors. Outcome parameters such as the adjusted incidence rate ratio (IRR), hazard ratio (HR), odds ratio (OR), rate ratio (RR) and the corresponding 95% confidence intervals (CI) were extracted and included in the meta-analysis if appropriate. Studies where such statistics could not be included in the meta-analysis were summarised in the narrative review. The primary outcome of interest was the risk of injuries following exposure to ADHD medications among patients with ADHD relative to patients or patient time without medications. Any data on physical injuries such as open wounds, fractures, transport accidents and falls recorded from all points of care, such as GP visits, hospitalisation and ED admissions, were extracted for inclusion.
Statistical Analysis
To estimate the association between the use of ADHD medications and incidence of injuries, the results of the included studies were combined using DerSimonian and Laird's random-effects model [12] to account for heterogeneity among studies. Analysis was performed on the adjusted estimates from the studies. The pooled estimates with 95% CI were calculated.
As the studies included in the analysis were conducted in different settings, we examined the extent of heterogeneity among studies using the Cochran Q test [12] , where a cut-off p value of 0.1 was considered significant for heterogeneity. Higgin's I 2 statistic was reported for each figure to indicate the degree of heterogeneity [12] . All analyses were conducted using Review Manager 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
Results
The PubMed, EMBASE, PsycINFO, CINAHL and Cochrane review databases were searched up to May 2017, with 1343, 444, 92, 122 and 0 records identified from each database, respectively, yielding 2001 records in total and 1322 records after removing duplicates (Fig. 1 ). Titles and abstracts were screened and full texts were retrieved for further assessment of 26 relevant records, of which 10 studies were found to be relevant. Six of the studies [6, [13] [14] [15] [16] [17] were conducted using nationwide databases, with two [15, 16] from the same nationwide claim database in Taiwan, three others [4, 18, 19] from insurance claim databases and one [5] from a GP database, all with substantial numbers of patients. All studies evaluated physical injuries as the outcome, which was defined as medically attended injuries at any point of care, identified diagnoses for injury on database records, or through entries for trauma-or transport-related injuries on medical records. Two studies [4, 13] limited the outcome to hospitalisations and three cohort studies [6, 14, 19] limited the outcome to ED visits from trauma-or transport-related injuries, while the remaining five included studies [5, [15] [16] [17] [18] attended injuries at all recorded points of care. All studies reported methylphenidate as a medication used in ADHD patients. ADHD medications studied were limited to methylphenidate in only two of the studies [6, 15] , while one study [5] included stimulant medications only and the remaining seven studies [4, 13, 14, [16] [17] [18] [19] included stimulant and non-stimulant medications. The characteristics and summary of results of the included studies are shown in Table 1 and Fig. 2a and b . The quality assessment of the included studies is shown in Table 2 . Four cohort studies [13, 15, 16, 18] received six to seven out of nine stars on the NOS scale, which indicates adequate quality. As all cohort studies compared treated individuals with untreated individuals, they lost two stars from the 'comparability' criteria. Six other studies [4-6, 14, 17, 19] received the full nine stars and were therefore considered to be of high quality. Six of the ten included studies [5, 6, 14, 16, 17, 19] reported significant association between injuries and ADHD medication use, with a lower risk/incidence of injury in treated patients or treated periods. While the remaining four studies [4, 13, 15, 18] did not find a significant association, the results were favourable towards the use of medications being associated with a lower risk of injuries. Three of the studies [4] [5] [6] were self-controlled caseseries studies, reporting within-individual comparisons only [20] . The remaining seven studies [13] [14] [15] [16] [17] [18] [19] were cohort studies, one [17] with within-individual analysis only, four [13, 15, 16, 18] with between-individual analyses only and two [14, 19] with both between-individual and within-individual analyses. The within-individual and between-individual analyses were included in separate meta-analyses. In each of the meta-analyses, the results were separated into subgroups of children and adults as the safety and effectiveness of ADHD medications are less well-studied in adults. The stratification of children and adults was according to definitions by investigators, with children defined as aged 18-21 years or lower [4-6, 13, 15, 17] and adults defined as aged 18 years or older [14, 16, 18, 19] .
Meta-Analysis of Within-Individual Analyses
Three SCCS and within-individual analysis of three cohort studies were included in the meta-analysis, comprising a total of 253,612 cases from databases in the US, Sweden, Hong Kong, Germany, Denmark and the UK [4-6, 14, 17, 19] . The study periods ranged from 1990 to 2014, with individual studies spanning between 4 and 15 years ( Table 1 ). The relative risk of injuries was significantly lower in the medicated periods (pooled RR 0.76, 95% CI 0.61-0.93) (Fig. 3) . No significant difference was observed between different within-individual study designs (subgroup Q-statistics = 2.52, p = 0.11, I 2 = 60.3%) (Fig. 3) . A lower risk of injuries was found (subgroup Q-statistics = 50.70, p\0.01, I 2 = 98.0%) in the medicated periods in adults (pooled RR 0.60, 95% CI [14, 19] 0.57-0.63) than in children (pooled RR 0.86, 95% CI 0.79-0.93). A high heterogeneity was found across the studies (Q-statistics = 126.42, p\0.01, I 2 = 96%) (Fig. 4) . The heterogeneity may be the result of the difference in the outcome measures, the statistical analysis used and the ADHD medications included across the six studies.
Meta-Analysis of Between-Individual Analyses
The between-individual results from six cohort studies [13-16, 18, 19] were included in the meta-analysis, comprising 2,347,656 ADHD patients across the cohorts, among which 1,964,855 patients received medications.
Two studies were from databases in the US [18, 19] , two from Taiwan [15, 16] , and one each from Sweden [14] and The Netherlands [13] . As Chien et al. [16] used the same database as Chen et al. [15] , the study by Chien et al. [16] was not included in the main meta-analysis for betweenindividual analyses to avoid double-up of results; however, it was substituted for the study by Chen et al. [15] in the sensitivity analysis to assess the impact on the overall results. The study periods ranged from 1996 to 2014, with individual studies spanning over 4-17 years (Table 1 ). The risk of injuries was significantly lower in the medicated individuals (pooled RR 0.88, 95% CI 0.85-0.92). A low heterogeneity was found between the studies (Q-statistics = 3.96, p = 0.41, I 2 = 0%) (Fig. 5 ). Sensitivity C cohort, SCC self-controlled cohort (only consider within-individual analysis), SCCS self-controlled case series (Fig. 6) .
In the subgroup analysis, the risk of injuries was found to be significantly lower in adults only (pooled RR 0.86, 95% CI 0.78-0.94), while no significant association was found in children (pooled RR 0.93, 95% CI 0.83-1.03) (Fig. 7) . However, no significant difference was found between the pooled estimates in children and adults (Qstatistics = 1.16, p = 0.28, I 2 = 13.9%).
Discussion
The results of all identified observational studies were largely favourable towards the use of medications being associated with a reduction in injuries when these are defined as ''medically attended physical injuries in the form of hospitalisations, emergency department visits or general practitioners visits''. Four of the seven cohort studies [14, 16, 17, 19] and two of three self-controlled case-series studies [5, 6] showed significant association between injuries and ADHD medication use. While the remaining three cohort studies [13, 15, 18] and one selfcontrolled case-series study [4] were unable to show a significant association, the non-significant finding may be due to insufficient statistical power. When the within-individual analysis results of three cohort studies [14, 17, 19] and three self-controlled caseseries studies [4] [5] [6] were pooled in the meta-analysis, reduction in injuries in patients was shown, with the incidence significantly lowered by 24% (95% CI 7-39%) during medication use as opposed to non-medicated periods, although a high heterogeneity was observed among the studies. The different statistics used in reporting the risk of injuries, including OR [17, 19] , IRR [4] [5] [6] and HR [14] , may have contributed to the heterogeneity. The different outcome measures, with studies including injury treated at all points of care [5, 17] , hospitalisations only [4] and ED visits only [6, 19] , may have also contributed to the heterogeneity. Furthermore, the variation in the ADHD medications in the studies ranging from methylphenidate only [6] to both stimulant and non-stimulant medications [4, 17, 19] could be another source of heterogeneity. While a significantly lower risk of injuries was found in both children and adults in the subgroup analysis, a greater effect was found in adults (40%, 95% CI 37-43%) compared with children (14%, 95% CI 7-21%) [Q-statistics = 50.70, p\0.01]. The heterogeneity found in the subgroup analysis for children (Q-statistics = 5.84, p = 0.12, I 2 = 49%) and adults (Q-statistics = 0.05, p = 0.83, I 2 = 0%) were low to moderate. The difference in effect in children and adults could be a contributor to the heterogeneity found in the overall meta-analysis of all within-individual analyses. Given such high heterogeneity, the results need to be interpreted cautiously.
When the between-individual results of the five cohort studies [13-15, 18, 19] were pooled in the meta-analysis, the risk of injuries in ADHD patients was also shown to be significantly lowered, by 12% (95% CI 8-15%), when medicated compared with not medicated. Low heterogeneity was found across the studies (Q-statistics = 3.57, p = 0.47, I 2 = 0%). In the subgroup analysis, significant association was not found in children (pooled RR 0.93, 95% CI 0.84-1.10), while a 12% lower risk (pooled RR 0.86, 95% CI 0.78-0.94) was found in adults. However, the test for subgroup difference did not show a significant difference in study results between children and adults (Qstatistics = 1.16, p = 0.28, I 2 = 13.9%). The non-significant result in children may be due to the insufficient power of the study design.
In two of the studies [5, 14] , a lower risk was found in treated males but not females. This may be due to the number of female cases identified being 33-85% fewer than that of males, resulting in insufficient statistical power to show significant findings.
Age-stratified analysis in two of the studies [6, 17] found that the benefit of injury reduction was greater in older adolescents, which is consistent with our finding from subgroup meta-analysis that the benefit of ADHD medications on injury reduction may be associated with age, with greater beneficial effect found in adults than in children.
Currently, injury prevention is not an indication for ADHD medications. In this study, we found that the use of ADHD medication was associated with a significantly lower risk of injury. This protective effect was clearly present not only in children and adolescents but also in adults, which highlights the importance of medication on the well-being of ADHD patients. However, pharmacological treatment is part of the comprehensive treatment programme for ADHD, which also incorporates psychosocial interventions. The initiation of drug treatment should be accompanied by careful clinical evaluation, including an accurate diagnosis, clear impairment in function due to ADHD, and weighting the risks and benefits of the medication.
Randomised clinical trials (RCTs) are recognised as the gold standard to evaluate the efficacy of pharmacological interventions. However, it is also recognised that RCTs are not an effective method to evaluate real-life outcomes due to the relatively short duration of trials and relatively small sample sizes. On the other hand, observational studies are more appropriate to evaluate outcomes in real-life practice. The major strength of observational studies using clinical/ administrative databases is the large sample sizes and long follow-up times. These provided a valuable basis to investigate the association between ADHD treatment and some rare adverse outcomes, such as suicidal attempts, psychosis and mortality [21] [22] [23] . This meta-analysis identified 10 large observational studies using clinical or administrative databases because these databases can provide information on injury-related medical encounters with a large sample size and long-term follow-up. However, observational studies are also prone to bias if confounding effects are not properly addressed. We conducted quality assessment on the included studies and all were of good quality. Six included studies [4-6, 14, 17, 19] had full stars on the NOS scale, applied within-individual study design. This could effectively remove time-invariant confounding effects to obtain an accurate estimate. On the other hand, the results from the four cohort studies (between-individual design) [13, 15, 16, 18] are similar to the pooled estimates of the within-individual design, which showed robustness of the results. In addition, the evidence from observational studies reflected the real-world effectiveness of the treatment, which could provide direct clinical implications for actual practice. With reference to the results of this study, injury prevention should be considered as one of the benefits of ADHD medication in clinical practice.
Strengths and Limitations
We undertook a rigorous systematic review and metaanalysis that included all relevant literature to date. Reviewer selection bias was minimised by using a predefined search strategy for selection and data extraction being conducted by two independent authors. Differences in study designs, exclusion criteria, control groups, duration of follow-up, covariates included and analysis model can affect the accuracy of pooled estimates. We observed moderate to high heterogeneity in the pooled estimates. This may represent the difference in the analysis for each study, in particular which covariates were included and what analysis model was used. Therefore, some of the results should be interpreted with caution. However, all studies were essentially measuring similar outcomes and there is no indication of large clinical heterogeneity to invalidate our meta-analysis and narrative reviews. More importantly the forest plots of the two analyses are consistent and make biological sense; thus, we believe it is appropriate to numerically summarise the results of some, but not all, studies in this systematic literature review. As the number of studies included in the meta-analysis is limited, a funnel plot was not performed as it would not reliably identify publication bias. In addition, the studies identified for meta-analysis are relatively recent (2009-2017) with similar results; therefore, we cannot exclude the possibility of publication bias. As a result, the pooled estimates may be overestimated.
Conclusions
The results from this meta-analysis support that pharmacological treatment could lower the risk of injuries by an average of 13%. The benefit of ADHD medications in injury reduction may be associated with age, with greater benefit in older adolescents and adults. While the traditional consideration of ADHD management has been on improving academic performance, trauma prevention is another important aspect of care and should be further considered in the broader clinical assessment and management of ADHD when medications are prescribed. 
